Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Head and Neck Cancer
Sarcoma
Solid Tumor
18 Years and older, Male and Female
PBI-MST-01 (primary)
NCI-2021-10892
Summary
This is a multi-center, open-label Phase 0 Master Protocol designed to study the
localized pharmacodynamics (PD) of anti-cancer therapies within the tumor
microenvironment (TME) when administered intratumorally in microdose quantities via the
CIVO device in patients with surface accessible solid tumors for which there is a
scheduled surgical intervention. CIVO stands for Comparative In Vivo Oncology. Multiple
substudies will include specified investigational agents and combinations to be
evaluated.
Objectives
CIVO is a research tool composed of a hand-held single-use sterile injector coupled with
fluorescent tracking microspheres called CIVO GLO that mark the sites of drug microdose
injection, enabling rapid assessment of multiple oncology drugs or drug combinations
simultaneously within a patient's tumor. Tumor responses to cancer treatments are highly
context-specific and often involve complex interactions between the anti-cancer therapy,
genetically diverse tumor cells, and a heterogeneous TME. This complexity is rarely
modeled accurately in preclinical translational models of cancer. By utilizing
intratumoral microdose injections with CIVO in advance of scheduled surgical
intervention, this study will evaluate anti-cancer therapies directly in patients each
with their own unique tumor genomic profile, intact TME, and immune system functional
status. Because the platform delivers microdose amounts of each test agent or combination
directly into the patient's tumor tissue, hypotheses can be tested earlier in the drug
development process, consistent with the goals of the 2006 FDA Exploratory IND Guidance
for Industry.
The CIVO device penetrates solid tumors and simultaneously delivers subtherapeutic
microdoses of up to eight anti-cancer agents or combinations of anti-cancer agents
co-injected with CIVO GLO into discrete regions of the tumor as drug columns. At the time
of the planned surgical intervention (at least four hours to up to seven days after the
CIVO microdose injection), the injected tumor tissue is then excised and tumor responses
are assessed via histological staining of tumor cross-sections sampled perpendicular to
each injection column. Co-injection with CIVO GLO enables identification of each
injection site during resection as well as in tissues stained for analysis. This Phase 0
Master Protocol is aimed at distinguishing promising candidates earlier in the drug
development process while also avoiding systemic toxicities associated with typical
clinical exposures to these therapies.
Eligibility
- Ability and willingness to comply with the study's visit and assessment schedule.
- Male or female = 18 years of age at Visit 1 (Screening).
- Pathologic diagnosis of [solid tumors] indicated in the relevant substudy(ies).
- Ability and willingness to provide written informed consent. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- At least one lesion (primary tumor, recurrent tumor, or metastatic lymph node) that is surface accessible for CIVO injection that contains viable minimum tumor tissue volume and characteristics (e.g., based on clinical evaluation, available pre-operative imaging, pre-injection ultrasound imaging, or pathology reports indicating lesion with appropriate viable tumor volume without excessive cysts or necrosis) and for which there is a planned surgical intervention. The patient's presentation, surgical and pathology plan may determine whether a lesion is eligible with respect to a given CIVO MID needle configuration.
- Female patients who:
- Are postmenopausal for at least one year before the screening visit, OR
- Are surgically sterile, OR
- Are of childbearing potential who agree to practice a highly effective method of contraception from the time of signing the Informed Consent Form (ICF) and during study participation OR agree to completely abstain from heterosexual intercourse.
- Agree to refrain from donating ova during study participation. Male patients, even if surgically sterile (i.e., status post-vasectomy), who:
- Agree to practice effective barrier contraception from the time of signing the ICF and during study participation OR agree to completely abstain from heterosexual intercourse.
- Agree to refrain from donating sperm during study participation.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.